Pfizer has made a substantial business in the vaccine domain. Being one of the largest healthcare providers it has also succeeded in making their strong hold in the vaccine sector. It is considered as the fourth largest company in the vaccine business. The only thing that has taken them so far with their vaccine campaign is Prevnar. Apart from that they do not really have any other drug. But now considering the potential of this industry, the company now plans to extend its portfolio by working on more vaccine related projects. Hence, Pfizer has completed its $635 million purchase from Baxter International Inc.
Moreover, the company is also doing business apart from extending its vaccine portfolio. The pharmaceutical giant Pfizer has completed a deal and merger with Wyeth Ltd. The deal with Wyeth Ltd makes it to the list of top ten pharmaceutical companies in India by market share. Indiatimes.com reported that “The Company had received approvals from the Bombay High Court earlier and today filed the order with the Registrar of Companies to conclude the merger process, Pfizer Ltd.”
This collaboration with Wyeth Ltd. places the pharmaceutical giant Pfizer among the top ten drug companies in India by market share. The company officials said “Pfizer Inc., USA, through its subsidiaries holds the majority stake in both companies and will continue to remain the majority shareholder with an around 63.9 per cent holding in Pfizer Ltd post-merger. The company has already completed the necessary steps to ensure a seamless transition and integration of the workforce into Pfizer Ltd.”
After signing a merger deal with Wyeth, the company is also focused to extend its vaccine portfolio. Hence Pfizer has completed its $635 million purchase from Baxter International Inc. of two vaccines and part of the factory in Orth, Austria, where they are made.
According to reports it is believed that the vaccines include combat against common group C strain of meningitis, a bacterial brain infection which causes death in a matter of seconds and spreads easily through throat sections and respiratory.
In a nutshell, the company is doing a good business in the market after failing signing deal with AstraZeneca.